These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36233396)

  • 1. PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment-A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters.
    Stanowska O; Kuczkiewicz-Siemion O; Dębowska M; Olszewski WP; Jagiełło-Gruszfeld A; Tysarowski A; Prochorec-Sobieszek M
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
    Wang X; Liu Y
    Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
    Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
    Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L; Wang XI; Ding J; Sun Q; Zhang S
    Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
    Ahn SG; Kim SK; Shepherd JH; Cha YJ; Bae SJ; Kim C; Jeong J; Perou CM
    Breast Cancer Res Treat; 2021 Jul; 188(1):165-178. PubMed ID: 33770313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer].
    Zhang J; Yuan P; Lei HZ; Liu XY; Li X; Ying JM; Sun GY; Wang SL; Lyu N
    Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):260-267. PubMed ID: 35316876
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression of PD-L1 using SP142 CDx in triple negative breast cancer.
    Al-Jussani GN; Dabbagh TZ; Al-Rimawi D; Sughayer MA
    Ann Diagn Pathol; 2021 Apr; 51():151703. PubMed ID: 33454500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer.
    Woo JW; Han EK; Suh KJ; Kim SH; Kim JH; Park SY
    Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38753066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and Prognostic Significance of Programmed Death Ligand-1 SP142 Expression in 132 Patients With Triple-negative Breast Cancer.
    Chu J; Yeo MK; Lee SH; Lee MY; Chae SW; Kim HS; DO SI
    In Vivo; 2022; 36(6):2890-2898. PubMed ID: 36309362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of the effects of chemotherapy on programmed death-ligand 1 expression in triple-negative breast cancer.
    Imanishi S; Morishima H; Gotoh T
    Jpn J Clin Oncol; 2022 Oct; 52(10):1167-1175. PubMed ID: 35766179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.
    Van Bockstal MR; Cooks M; Nederlof I; Brinkhuis M; Dutman A; Koopmans M; Kooreman L; van der Vegt B; Verhoog L; Vreuls C; Westenend P; Kok M; van Diest PJ; Nauwelaers I; Laudus N; Denkert C; Rimm D; Siziopikou KP; Ely S; Zardavas D; Roberts M; Floris G; Hartman J; Acs B; Peeters D; Bartlett JMS; Dequeker E; Salgado R; Giudici F; Michiels S; Horlings H; van Deurzen CHM
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
    García-Teijido P; Cabal ML; Fernández IP; Pérez YF
    Clin Med Insights Oncol; 2016; 10(Suppl 1):31-9. PubMed ID: 27081325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Azim HA; Shohdy KS; Elghazawy H; Salib MM; Almeldin D; Kassem L
    Biomarkers; 2022 Dec; 27(8):764-772. PubMed ID: 35980714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-infiltrating lymphocytes status, programmed death-ligand 1 expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses.
    Xiao X; Jin S; Zhangyang G; Xiao S; Na F; Yue J
    Gland Surg; 2022 Jun; 11(6):1037-1046. PubMed ID: 35800740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
    Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
    Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
    [No Abstract]   [Full Text] [Related]  

  • 18. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
    Noske A; Möbus V; Weber K; Schmatloch S; Weichert W; Köhne CH; Solbach C; Ingold Heppner B; Steiger K; Müller V; Fasching P; Karn T; van Mackelenbergh M; Marmé F; Schmitt WD; Schem C; Stickeler E; Loibl S; Denkert C
    Eur J Cancer; 2019 Jun; 114():76-88. PubMed ID: 31075727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Wimberly H; Brown JR; Schalper K; Haack H; Silver MR; Nixon C; Bossuyt V; Pusztai L; Lannin DR; Rimm DL
    Cancer Immunol Res; 2015 Apr; 3(4):326-32. PubMed ID: 25527356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PD-L1 in Locally Advanced Breast Cancer and Its Impact on Neoadjuvant Chemotherapy Response.
    Hussein MA; Ismail HA; Sakr M; Nouh MA
    Asian Pac J Cancer Prev; 2022 Jun; 23(6):2095-2103. PubMed ID: 35763653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.